Long-term antidyskinetic efficacy of amantadine in Parkinson's disease

Movement Disorders

Volumn 25, Issue 10, 2010, Pages 1357-1363

  Wolf, Elisabeth ^a   Seppi, Klaus ^a   Katzenschlager, Regina ^b   Hochschorner, Guenter ^c   Ransmayr, Gerhard ^d   Schwingenschuh, Petra ^e   Ott, Erwin ^e   Kloiber, Iris ^f   Haubenberger, Dietrich ^c   Auff, Eduard ^c   Poewe, Werner ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Wiener Krankenanstaltenverbund   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d KEPLER UNIVERSITY HOSPITAL   (Austria)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

Author keywords

Amantadine; Dyskinesia; Parkinson's disease

Indexed keywords

AMANTADINE SULFATE; HOFCOMANT; LACTOSE; LEVODOPA; MICROCRYSTALLINE CELLULOSE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSKINESIA; FALLING; FEMALE; FOLLOW UP; HUMAN; MALE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; AGED; AGED, 80 AND OVER; AMANTADINE; ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77953184604     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23034     Document Type: Article

References (26)

1. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 2000;23:34-44.
2. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. NEJM 2000;342:1484-1491.
3. Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986; 36:1528-1530.
4. Antonelli T, Fuxe K, Agnati L, et al. Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias. J Neurol Sci 2006;248:16-22.
5. Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001;27:1829-1834.
6. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN. AMPA receptors blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 2000;54:1589-1595.
7. Olanow CW, Damier P, Goetz CG, et al. Multicenter, openlabel, trial of sarizotan in Parkinson disease patients with levodopa- induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 2004;27:58-62.
8. Goetz CG, Damier P, Hicking C, et al. Sarizotane as a treatment ofr dykinesias in parkinson's disease: a double-blind Placebo-controlled trial. Mov Disord 2007;22:179-186.
9. Rascol O, Arnulf I, Peyro-Saint Paul H, et al. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 2001;16:708-713.
10. Manson AJ, Iakovidou E, Lees AJ. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000;15:336-337.
11. Lewitt PA, Guttmann M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008;63:295-302.
12. Bara-Jimenez W, Bibbiani F, Morris MJ, et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 2005;20:932-936.
13. Luginger E, Wenning GK, Boesch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000;15:873-878.
14. Verhagen Metman L, Del Dotto P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326. (Pubitemid 28240346)
15. Thomas A, Iacono D, Luciano AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:141-143.
16. Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacology 2000;23:82-85.
17. Da Silva-Junior FP, Braga-Neto P, Sueli Monte F, De Bruin VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord 2005;11:449-452.
18. Rajput AH, Rajput A, Lang AE, et al. New use for an old drug: amantadine benefits levodopa induced dyskiensias. Mov Disor 1998;13:851-854.
19. Ruicka E, Streiova H, Jech R, et al. Amantadine infusion treatment of motor fluctuations and dyskinesias in Parkinson's disease. J Neural Trans 2000;102:1297-1306.
20. Verhagen LM, Del Dotto P, Lepoole K, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-uo Study. Arch Neurol 1999;56:1383-1386.
21. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000; 23:75-81.
22. Schwab R, Poskanzer DC, England AC, Young RR. Amantadine in Parknson's disease: review of more than two years experience. JAMA 1972;222:792-795.
23. Dallos V, Healthfield K, Stone P, Allen FAD. Use of amantadine in Parkinson's disease. Results of a double-trial. BMJ 1970;4:24-26.
24. Factor S, Molho E, Brown D. Acute delirium after withdrawl of amantadine in Parkinson's disease. Neurology 1998;50:1456-1458.
25. Simpson DM, Davis GC. Case report of neuroleptic malignant syndrome associated with withdrawl from Amantadine. Am J Psychiatry 1984;141:796-797.
26. Hamburg P, Weilburg JB, Cassem NH, Cohen L, Brown S. Relapse of neuroleptic malignant syndrome with early discontinuation of amantadine therapy. Compr Psychiatry 1986;27:272-275.